Trial Profile
A Phase II Study for Evaluating Anti-tumor Efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma or Pleural Effusion
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AMC_TAGRISSSO
- 23 Apr 2021 Status changed from active, no longer recruiting to completed.
- 21 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2020.